CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the colon
      Google Scholar   
Citation:
Ann. Oncol. vol 25 (supple 2) ii112-ii113
Meeting Instance:
ESMO GI 2014
Year:
2014
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pub
Note:
Presented at ESMO 16th World Congress on Gastrointestinal Cancer, 25–28 June 2014, Barcelona, Spain
Methodological:
No
Biospecimen:
No
DataSharing:
No
Parents:
None
Children:
2637  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                                     
Primary Study
CALGB-80405
Secondary Studies:
Phases:
3
Keywords: